Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Apollomics (Nasdaq: APLM) entered a $2.0 million unsecured convertible promissory note with CEO Hung-Wen (Howard) Chen on March 30, 2026 to provide working capital for clinical development and general operations.The Note bears 0% interest and will automatically convert upon a subsequent equity financing of at least $10.0 million at a 20% discount to that financing's lowest per-share price. The independent Audit Committee and Board approved the related-party terms, with the CEO abstaining from the vote.

Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced

Apollomics (Nasdaq: APLM) entered a settlement resolving Cayman Islands litigation with TWVC related to preferred‑share redemptions before its 2023 merger with Maxpro Capital Acquisition Corporation. The company agreed to pay US$5.0 million in cash in several installments over two years plus approximately US$879,757.78 in legal expenses.TWVC will withdraw all claims and the parties are submitting the Settlement Agreement for court approval to conclude the proceedings. The original damages claimed by TWVC were approximately US$40 million, as disclosed in Apollomics' April 2025 Form 20‑F.

Apollomics (Nasdaq: APLM) said Nasdaq notified the company on October 14, 2025 that the Listing Qualifications Staff determined Apollomics is in compliance with Nasdaq continued listing requirements.As a result, Nasdaq cancelled the previously scheduled appeal hearing and Apollomics securities will remain listed and continue to trade on The Nasdaq Stock Market. The company had earlier filed an application to appeal a delisting notification and requested a hearing before a Nasdaq Hearings Panel.

The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq: APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively, on October 15, 2025. Trading in the

Apollomics (NASDAQ: APLM) reported its full year 2024 financial results and clinical updates. The company secured a strategic collaboration with LaunXP for vebreltinib development, bringing in a $10 million upfront payment. Key clinical highlights include a 43% objective response rate in non-CNS MET fusion solid tumors and 30% response rate in high MET gene copy number patients.Financial results show cash position of $9.8 million as of December 31, 2024, compared to $37.8 million in 2023. R&D expenses decreased to $24.6 million from $34.2 million, while administrative expenses reduced to $17.8 million from $20.6 million. Net loss for 2024 was $(53.9) million or $(52.80) per share, improved from $(172.6) million loss in 2023.The company implemented strategic expense reductions and expects current cash, combined with the LaunXP payment, to fund operations into Q1 2026.

Strategic partnership brings $10M upfront plus $50M in milestones for innovative lung cancer combination therapy. Expansion targets key Asian markets. Full analysis inside.

Key cancer drug uproleselan falls short in Phase 3 trial for acute myeloid leukemia, showing reduced survival rates compared to standard therapy, leading to program termination.